OMGAQ (Omega Therapeutics) LT-Debt-to-Total-Asset: 0.74 (As of Sep. 2024)


OMGAQ Omega Therapeutics Inc OMGAQ
16 GF Score
Price $0.00
View Full Analysis

What is Omega Therapeutics LT-Debt-to-Total-Asset?

Omega Therapeutics OMGAQ +50.00% 16 LT-Debt-to-Total-Asset is 0.74 as of Sep. 2024. GuruFocus rates OMGAQ with a GF Score™ of 16/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Omega Therapeutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.74.

Omega Therapeutics's long-term debt to total assets ratio increased from Sep. 2023 (0.53) to Sep. 2024 (0.74). It may suggest that Omega Therapeutics is progressively becoming more dependent on debt to grow their business.

Omega Therapeutics  (OTCPK:OMGAQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Omega Therapeutics LT-Debt-to-Total-Asset Related Terms

Omega Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Omega Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omega Therapeutics LT-Debt-to-Total-Asset Chart

Omega Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
1.94 0.31 0.09 0.12 0.55

Omega Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.55 0.61 0.66 0.74
OMGAQ
16GF Score
Omega Therapeutics Inc OMGAQ
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omega Therapeutics LT-Debt-to-Total-Asset Calculation

Omega Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=113.128/204.366
=0.55

Omega Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=112.214/152.727
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.74 mean?
Omega Therapeutics (OMGAQ) has a LT-Debt-to-Total-Asset of 0.74 as of Sep. 2024. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Omega Therapeutics and its competitors.
Is Omega Therapeutics' LT-Debt-to-Total-Asset too high?
Omega Therapeutics' current LT-Debt-to-Total-Asset is 0.74. Overall, Omega Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Omega Therapeutics' LT-Debt-to-Total-Asset compare to ENDV and ORGS?
Omega Therapeutics' LT-Debt-to-Total-Asset of 0.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Omega Therapeutics and its competitors. Omega Therapeutics's current LT-Debt-to-Total-Asset is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omega Therapeutics stock overvalued right now?
Omega Therapeutics (OMGAQ) has a current LT-Debt-to-Total-Asset of 0.74. The current LT-Debt-to-Total-Asset is 0.74. Omega Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Omega Therapeutics (OMGAQ), the current LT-Debt-to-Total-Asset is 0.74 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omega Therapeutics Business Description

Address 140 First Street, Suite 501, Cambridge, MA, USA, 02141
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
16GF Score

Get the complete analysis for OMGAQ

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price